Abstract
Introduction Respiratory syncytial virus (RSV) can cause severe outcomes among adults. However, RSV incidence in adults is frequently underestimated due to non-specific symptomatology, limited standard-of-care testing, and lower test sensitivity compared to infants. We conducted a retrospective observational study to estimate RSV-attributable incidence of hospitalizations among adults in Germany between 2015 and 2019.
Methods Information on hospitalizations and the number of people at risk of hospitalization (denominator) was gathered from a Statutory Health Insurance (SHI) database. A quasi-Poisson regression model accounting for periodic and aperiodic time trends and virus activity was fitted to estimate the RSV-attributable incidence rate (IR) of four specific cardiovascular hospitalizations (arrhythmia, ischemic heart diseases, chronic heart failure exacerbations, cerebrovascular diseases) and four specific respiratory hospitalizations (influenza/pneumonia, bronchitis/bronchiolitis, chronic lower respiratory tract diseases, upper respiratory tract diseases).
Results RSV-attributable IRs of hospitalizations were generally increasing with age. Among cardiovascular hospitalizations in adults aged ≥60 years, arrhythmia and ischemic heart diseases accounted for the highest incidence of RSV-attributable events, followed by chronic heart failure exacerbation, with annual IR ranges of 157– 260, 133–214, and 105–169 per 100,000 person-years, respectively. The most frequent RSV-attributable respiratory hospitalizations in adults aged ≥60 years were for chronic lower respiratory tract diseases and bronchitis/bronchiolitis, with annual IR ranges of 103–168 and 77–122 per 100,000 person-years, respectively.
Conclusion RSV causes a considerable burden of respiratory and cardiovascular hospitalizations in adults in Germany, similar to other respiratory viruses (e.g., influenza and SARS-CoV-2). This highlights the need to implement effective prevention strategies, especially for older adults.
Key Summary Points
Respiratory syncytial virus (RSV) disease burden in adults is significant yet often remains unrecognized due to unspecific symptoms, lack of routine testing and lower test sensitivity compared to infants.
Using a quasi-Poisson regression time-series model, we estimated the age-stratified RSV-attributable incidence of specific cardiovascular and respiratory hospitalizations in Germany between 2015 and 2019.
Estimated cardiorespiratory RSV hospitalization rates increased with age and were significantly higher in older adults.
Arrhythmia, ischemic heart diseases, and chronic lower respiratory tract disease exacerbation were the most frequent causes of RSV-attributable cardiovascular and respiratory hospitalizations.
RSV causes a considerable burden of respiratory and cardiovascular hospitalizations among adults in Germany, and effective RSV vaccines could improve public health outcomes, especially for older adults.
Competing Interest Statement
Aleksandra Polkowska-Kramek, Robin Bruyndonckx, Worku Biyadgie Ewnetu, Pimnara Peerawaranun, Maribel Casas, Thao Mai Phuong Tran are employees of P95 Epidemiology & Pharmacovigilance, which received funding from Pfizer to conduct the research described in this manuscript and for manuscript development. Caihua Liang, Caroline Lade, Lea Johanna Bayer, Bennet Huebbe, Gordon Brestrich, Christof von Eiff, Bradford D. Gessner, and Elizabeth Begier are Pfizer employees and may own Pfizer stock. Gernot Rohde is an expert in the field of RSV and received an honorarium from Pfizer for input on the study design.
Funding Statement
This study was funded by Pfizer Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used aggregated and anonymized data, therefore not requiring approval from Institutional Review Boards or Ethical Committees or informed consent from patients. The study was conducted following legal and regulatory requirements and research practices described in the Good Epidemiological Practice guidelines issued by the International Epidemiological Association.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The datasets generated and/or analyzed during this study are not publicly available (data provider’s restrictions). Weekly counts of hospitalized cases and extrapolation factors were provided by the Gesundheitsforen Leipzig GmbH.
